The 16 linked references in paper O.  Shakhmatova O., A. Komarov L., О. Шахматова О., А. Комаров Л. (2018) “ПРАСУГРЕЛ В ЛЕЧЕНИИ ПАЦИЕНТОВ С ОСТРЫМ КОРОНАРНЫМ СИНДРОМОМ И ЧРЕСКОЖНЫМ КОРОНАРНЫМ ВМЕШАТЕЛЬСТВОМ: СОВРЕМЕННОЕ СОСТОЯНИЕ ПРОБЛЕМЫ // PRASUGREL FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES AND PERCUTANEOUS CORONARY INTERVENTION: STATUS UPDATE ON THE PROBLEM” / spz:neicon:aterotromboz:y:2018:i:1:p:52-66

  1. Farid nA, Kurihara A, Wrighton sA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol, 2010, 50: 126–142. doi: 10.1177 / 0091270009343005.
  2. Valgimigli M, Bueno H, Byrne RA et al. 2017 esC focused update on dual antiplatelet therapy in coro‑ nary artery disease developed in collaboration with eACts. european Heart Journal, 2017, 0: 1–48. doi: 10.1093 / eurheartj / ehx419.
  3. Wilcox R, Iqbal K, Costigan t et al. An analysis of tRIton‑tIMI 38, based on the 12 month recom‑ mended length of therapy in the european label for prasugrel. Curr Med Res opin, 2014, 30: 2193–205. doi: 10.1185 / 03007995.2014.944638.
  4. Angiolillo DJ, Rollini F, storey RF et al. International expert Consensus on switching Platelet P2Y12 Receptor – Inhibiting therapies. Circulation. 2017, 136: 1955–1975. doi: 10.1161 / CIRCULAtIonAHA.117.031 164.
  5. Alexopoulos D, Xanthopoulou I, Deftereos s et al. In‑hospital switching of oral P2Y12 inhibitor treat‑ ment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short‑term outcome. Am Heart J, 2014, 167: 68–76.e2. doi: 10.1016 / j. ahj.2013.10.010.
  6. Clemmensen P, Grieco n, Ince H et al. MULtIPRAC study investigators. MULtInational non‑interven‑ tional study of patients with st‑segment eleva‑ tion myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopido‑ grel: the european MULtIPRAC Registry. eur Heart J Acute Cardiovasc Care, 2015, 4: 220–229. doi: 10.1177 / 2 0 4 8 872 614 5474 4 9.
  7. Bagai A, Peterson eD, Honeycutt e et al. In‑hospital switching between adenosine diphosphate recep‑ tor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary prac‑ tice from the tRAnsLAteACs study. eur Heart J Acute Cardiovasc Care, 2015, 4: 499–508. doi: 10.1177 / 2048872614564082.
  8. schiele F, Puymirat e, Bonello L et al. switching between thienopyridines in patients with acute myocardial infarction and quality of care. open Heart, 2016, 3: e000384. doi: 10.1136 / openhrt‑2015–000384.
  9. Luca L, Leonardi s, Cavallini C et al. eYesHot Investigators. Contemporary antithrombotic strate‑ gies in patients with acute coronary syndrome admit‑ ted to cardiac care units in Italy: the eYesHot study. eur Heart J Acute Cardiovasc Care, 2015, 4: 441–452. doi: 10.1177 / 2048872614560505.
  10. Bagai A, Wang Y, Wang tY et al. In‑hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percu‑ taneous coronary intervention: insights into contem‑ porary practice from the national Cardiovascular Data Registry. Circ Cardiovasc Interv, 2014, 7: 585–593. doi: 10.1161 / CIRCInteRVentIons.114.001555.
  11. Zettler Me, Peterson eD, McCoy LA et al. tRAnsLAte‑ ACs Investigators. switching of adenosine diphos‑ phate receptor inhibitor after hospital discharge among myocardial infarction patients: insights from the treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of treatment Patterns and events after Acute Coronary syndrome (tRAnsLAte‑ACs) observational study. Am Heart J, 2017, 183: 62–68. doi: 10.1016 / j.ahj.2016.10.006.
  12. Luca L, D’Ascenzo F, Musumeci G et al. Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary inter‑ vention: the sCoPe registry. euroIntervention, 2017, 13: 459–466. doi: 10.4244 / eIJD‑17–00092.
  13. Cuisset t, Deharo P, Quilici J et al. Benefit of switch‑ ing dual antiplatelet therapy after acute coronary syndrome: the toPIC (timing of Platelet Inhibition After Acute Coronary syndrome) randomized study. eur Heart J, 2017 nov 1, 38 (41 ): 3070–3078. doi: 10.1093 / eurheartj / ehx175.
  14. sibbing D, Aradi D, Jacobshagen C et al. Guided de‑ escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (tRoPICAL‑ACs): a randomised, open‑label, multicentre trial. Lancet, 2017, 390: 1747– 1757. doi: 10.1016 / s0140–6736 (17) 32155–4.
  15. Motovska Z, Hlinomaz o, Kala P et al. 1‑Year outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction treated With Prasugrel Versus ticagrelor. J Am Coll Cardiol, 2018 Jan 30, 71 (4): 371– 381. doi: 10.1016 / j.jacc.2017.11.008.
  16. Danchin n, Lettino M, Zeymer U et al. Use, patient selection and outcomes of P2Y12 receptor inhibi‑ tor treatment in patients with steMI based on contemporary european registries. eur Heart J Cardiovasc Pharmacother, 2016, 2: 152–167. doi: 10.1093 / ehjcvp / pvw003.